Cognition Therapeutics (CGTX)

Executive Summary

Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Its lead candidate, CT1812, is an orally available, brain-penetrant sigma-2 receptor modulator in Phase 2 development for Alzheimer's disease. The company is evaluating CT1812 in the SHINE and SHIMMER trials for mild-to-moderate Alzheimer's, with topline data expected in the second half of 2025. Beyond Alzheimer's, Cognition is exploring CT1812 in dementia with Lewy bodies (Phase 2) and preclinical geographic atrophy. Despite a high-risk profile typical of early-stage biotech, the sigma-2 platform offers a novel mechanism targeting proteinopathies, potentially differentiating it from anti-amyloid therapies. The company's cash position and recent funding provide runway through key data readouts, but dilution risk remains. Investors should monitor upcoming Phase 2 results and potential partnership opportunities.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 SHIMMER Trial Topline Data for CT1812 in Mild-to-Moderate Alzheimer's Disease30% success
• Q2 2026Phase 2 Trial in Dementia with Lewy Bodies (DLB) Interim or Topline Results25% success
• Q4 2026Initiation of Phase 1/2 Trial in Geographic Atrophy (GA)60% success